Search

Displaying results 1591 - 1600 of 4207 in total
  1. Drug

    Tetraethylammonium

    go.drugbank.com/drugs/DB08837
    Investigational

    The only marketed drug containing tetraethylammonium was a combination drug called Fosglutamina B6, but this drug has now been discontinued. … Because of its inhibitory actions at the autonomic ganglia, tetraethylammonium was thought to be a potential therapeutic vasodilator but serious toxic effects were found.

  2. Drug

    Phenyl salicylate

    go.drugbank.com/drugs/DB11071
    Approved

    It is an active ingredient in some pharmaceutical products as a mild analgesic for pain relief by releasing salicylate (found in [DB00945] ). … It is synthesized by heating salicylic acid with phenol [L2468], [MSDS]. Phenyl salicylate is used as a food additive in the USA [L2479].

  3. Drug

    Selinexor

    go.drugbank.com/drugs/DB11942
    ApprovedInvestigational

    [L7117,L7120,L10145] This condition is typically treated with high dose [bortezomib] and [dexamethasone] chemotherapy followed by an autologous stem-cell transplant. … [L10145] The use of selinexor in combination with [bortezomib] and [dexamethasone] was approved by Health Canada in June 2022 for the treatment of multiple myeloma in adult patients who have received at

  4. Drug

    Alglucerase

    go.drugbank.com/drugs/DB00088
    ApprovedWithdrawn

    Alglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase. … Alglucerase was first approved by the FDA in 1991;[A254816] however, it was later discontinued from the market.

  5. Drug

    Human papillomavirus type 33 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10311
    ApprovedInvestigational

    It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 33. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Type 33 which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae

  6. Drug

    Human papillomavirus type 45 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10312
    ApprovedInvestigational

    It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 45. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Type 45 which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae

  7. Drug

    Human papillomavirus type 58 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10314
    ApprovedInvestigational

    It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 58. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Type 58 which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae

  8. Drug

    Cethromycin

    go.drugbank.com/drugs/DB06419
    Investigational

    [L14006, A203369] However, after completing phase III clinical trials, it was deemed safe but not sufficiently efficacious by the FDA. … [A203369] Cethromycin represents a joint development effort by Abbott Laboratories, Taisho Pharmaceuticals, and Advanced Life Sciences, intended to be marketed under the trade name Restanza for the treatment

  9. Drug

    Naxitamab

    go.drugbank.com/drugs/DB15965
    ApprovedInvestigational

    [A224604] The first anti-GD2-monoclonal IgG antibody to be approved by the FDA for the treatment of neuroblastoma was [dinutuximab] under the brand name Unituxin in 2015. … [L24929] Naxitamab-gqgk (Danyelza) was granted accelerated approval by the FDA in November 2020 for the treatment of high-risk relapsed/refractory neuroblastoma of the bone or bone marrow.

  10. Drug

    Avelumab

    go.drugbank.com/drugs/DB11945
    ApprovedInvestigational

    [A261496] Avelumab was first approved by the FDA on March 23, 2017. … [A261496] On September 18 and December 18 of the same year, it was also granted approval by EMA [L48126] and Health Canada,[L48171] respectively.